| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Gilead Sciences, Inc.'s insiders have reduced their positions by a net 15,000 shares worth roughly $2.0M.
GILD sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 92.1K | $12.74M | - | |
| Other | 46.6K | $6.45M | - | |
| Other | 27.9K | $3.85M | - | |
| CFO | 27.9K | $3.85M | - | |
| VP | 20.0K | $2.77M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 3, 2017 | Alton Gregg H | EVP Comm&Acs Ala, Corp&Med Aff | Sell | 5,000 | $71.06 | $355,295.00 | -4.6% | |
| Jun 1, 2017 | Martin John C | Executive Chairman | Sale+OE | 73,333 | $65.24 | $4,784,530.92 | -2.2% | |
| Jun 1, 2017 | Alton Gregg H | EVP Comm&Acs Ala, Corp&Med Aff | Sell | 5,000 | $65.02 | $325,113.50 | -4.4% | |
| May 9, 2017 | Cogan John Francis | Director | Sale+OE | 9,943 | $67.25 | $668,666.75 | -15.9% | |
| May 1, 2017 | Martin John C | Executive Chairman | Sale+OE | 73,333 | $68.31 | $5,009,428.56 | -2.3% | |
| May 1, 2017 | Alton Gregg H | EVP Comm&Acs Ala, Corp&Med Aff | Sell | 5,000 | $68.31 | $341,529.00 | -4.2% | |
| Apr 3, 2017 | Martin John C | Executive Chairman | Sale+OE | 73,333 | $67.18 | $4,926,286.53 | -1.2% | |
| Mar 30, 2017 | Alton Gregg H | EVP Comm&Acs Ala, Corp&Med Aff | Sell | 5,000 | $67.48 | $337,392.00 | -4.1% | |
| Mar 1, 2017 | Martin John C | Executive Chairman | Sale+OE | 73,333 | $70.38 | $5,161,205.87 | -2.3% |